Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

IFN-γ increases δ-globin gene expression through activation of the JAK/STAT pathway in erythroid cells.

Blood·2025
Same author

Olfactomedin 4 in cancer development and progression.

Biochimica et biophysica acta. Reviews on cancer·2025
Same author

Differential MicroRNA Profiles Associated With the Hydroxyurea-Inducible <i>SAR1A</i> Gene.

Journal of hematology·2025
Same author

NIDDK: Celebrating 75 Years of Advancing Diabetes Research.

Diabetes care·2025
Same author

NIDDK: Celebrating 75 Years of Advancing Diabetes Research.

Diabetes·2025
Same author

Olfactomedin 4 promotes gastric cancer cell G2/M progression and serves as a therapeutic target in gastric adenocarcinoma.

Carcinogenesis·2025

相关实验视频

Updated: Jul 12, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

照亮可药性基因组:通往进步的途径

Karlie R Sharma1, Christine M Colvis1, Griffin P Rodgers2

  • 1National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd, Bethesda, MD 20892, USA.

Drug discovery today
|October 27, 2023
PubMed
概括

启发可使用药物的基因组计划开发了研究不足向蛋白质的资源. 这些工具旨在推动G蛋白结合受体,离子通道和激酶的研究,以获得更好的人类健康结果.

更多相关视频

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.2K

相关实验视频

Last Updated: Jul 12, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.2K

科学领域:

  • 基因组学就是基因组学.
  • 蛋白质组学是指蛋白质组学.
  • 药物发现 药物发现 药物发现

背景情况:

  • 人类基因组包含约4500个可药物治疗的基因,但只有很小一部分是现有的药物准的.
  • 许多可用药物的蛋白质,特别是G蛋白结合受体 (GPCR),离子通道和激酶,仍未得到充分研究.
  • 美国国家卫生研究院启动了"照明可药性基因组计划",以解决这一知识缺口.

研究的目的:

  • 审查和介绍由照明可药物基因组计划创建的资源.
  • 授权科学界调查研究不足的生物目标.
  • 加快新疗法的发现,这些疗法有可能影响人类健康.

主要方法:

  • 本综述综合了来自"阐明可药性基因组计划"的成果和资源.
  • 该计划的重点是为三个关键蛋白家族生成数据和工具:GPCRs,离子通道和激酶.
  • 资源的设计是为了广泛的可访问性和研究人员的应用.

主要成果:

  • 该计划已经产生了一套有价值的资源,用于研究低目标蛋白质.
  • 这些资源有助于对GPCRs,离子通道和激酶的生物学进行更深入的探索.
  • 开发的工具旨在弥合研究不足的基因和治疗开发之间的差距.

结论:

  • "照亮可使用药物的基因组计划"为推进关键蛋白质家族研究提供了必不可少的工具.
  • 这些资源将使科学家能够探索以前研究不足的生物学领域.
  • 该计划的成果有望对开发新型人类健康干预措施作出重大贡献.